Care and Contamination: What BRSR Demands From India's Healthcare and Pharma Industry

India's healthcare sector serves 1.4 billion people, employs over 7.5 million workers, and was on track to reach $596 billion by 2025. Yet it accounts for just 6% of the total market capitalisation of the top 1,000 NSE-listed companies - a sector massive in social footprint but comparatively small in the market-cap terms that usually drive ESG scrutiny. That mismatch has let healthcare's real ESG risks sit quietly out of view for years: biomedical waste bins, antibiotic residue in manufacturing effluent, burned-out clinical staff. None of it looks like a coal plant's emissions or a cement kiln's Scope 1 number, but BRSR for healthcare companies now has to account for it all.
Why Healthcare Carries a Different Weight
A new sector-specific ESG framework for healthcare and pharma, jointly developed by Aspire Impact and Aspire Circle with backing from Quadria Capital and HealthQuad, and shaped with input from Fortis, Apollo, and Tata Capital Healthcare Fund, was unveiled in 2025 specifically because generic ESG scoring wasn't capturing what actually matters in this sector.
The framework introduces 80 sector-agnostic indicators alongside 27 healthcare-specific ones, built to assess risks like biomedical waste, antimicrobial resistance, and unequal access to care, while separately identifying opportunities in green hospital infrastructure, digital health, and affordable drug development. That distinction between healthcare-specific risk and opportunity is the clearest signal yet that BRSR for healthcare companies needs its own lens, not a borrowed one from manufacturing or energy.
What BRSR Actually Requires From Healthcare and Pharma Companies
For a listed hospital chain, diagnostics company, or pharmaceutical manufacturer, BRSR Principle 6 still covers the standard environmental ground - energy use, water withdrawal, waste generated and how it's disposed of. But two other principles carry unusually heavy weight in this sector. Principle 3, covering employee wellbeing and safety, has to account for a workforce that includes doctors, nurses, and pharma plant workers facing occupational hazards ranging from biological exposure to burnout, in an industry where staff shortages and long shifts are already a known structural problem. Principle 8, covering community impact, has to reckon with something most sectors never touch directly: whether the company's core product or service is actually accessible to the people who need it, not just profitable to the people who can pay for it.
Biomedical waste sits squarely within Principle 6, but it deserves its own conversation because it behaves very differently from ordinary industrial waste. Biomedical waste management in India is governed by the Bio-Medical Waste Management Rules, 2016, and their subsequent amendments, enforced through CPCB guidelines that increasingly expect digital tracking of waste from generation to final disposal. Biomedical waste makes up only around 1% of India's total waste stream by volume. Still, it's highly infectious and toxic, which is exactly why it's regulated so much more tightly than its size would suggest.
It's also growing faster than the healthcare sector itself, with biomedical waste volumes in India rising at roughly 7% annually, driven by more hospitals, more diagnostic centres, medical tourism, and an ageing population. For a hospital chain's BRSR filing, biomedical waste management isn't a rounding-error disclosure. It's often the single most scrutinised environmental line item the company reports.
The Pharma Manufacturing Problem Few People Talk About
Pharmaceutical manufacturing carries an environmental footprint that looks nothing like a hospital's. India's pharmaceutical production has grown at roughly 8% annually over the past decade, more than twice the global average, built substantially on active pharmaceutical ingredient manufacturing clustered in a handful of industrial belts. That concentration has created one of the sector's most persistent and least discussed ESG issues: pharmaceutical effluent. Indian regulators and researchers have documented for years that around API manufacturing hubs, antibiotic and drug residues entering local water systems have been linked to antimicrobial resistance developing in the surrounding environment, not just inside a hospital ward.
This is where antimicrobial resistance stops being a purely medical or public health topic and becomes a direct BRSR disclosure issue for healthcare companies. A pharma manufacturer's effluent treatment standards, and whether they go beyond bare regulatory minimums for antibiotic residue discharge, are now recognised as a material environmental and social risk under sector-specific ESG frameworks, not just a compliance footnote. Companies that have invested in this- several large Indian pharma players already report on effluent treatment, water discharge quality, and third-party assurance in growing detail in their BRSR and sustainability filings- are increasingly using that data as evidence against a real reputational and regulatory risk, not just a disclosure exercise for its own sake.
Green Hospital Infrastructure and the Access Question
The flip side of healthcare's risk profile is that some of the sector's biggest ESG opportunities are things no other industry can really claim. Green hospital infrastructure, energy-efficient buildings, better water and waste management systems, and cleaner HVAC design for infection control address both the environmental disclosure a hospital chain needs under Principle 6 and the patient safety outcomes that matter to Principle 3. Digital health platforms that extend diagnostic and consultation access into underserved areas do double duty too, improving both the company's operational efficiency and its Principle 8 disclosure on community impact and access to essential services, which for healthcare is a far more direct, literal test than it is for almost any other sector filing BRSR.
Affordable drug development sits in the same category. A pharmaceutical company's pricing and access strategy for essential medicines is, in a very real sense, its core ESG story, not a side note to it. This is the clearest place where BRSR for healthcare companies diverges from every other sector covered in this series. For power or cement, the ESG story is almost entirely about limiting harm. For healthcare, a meaningful share of the ESG story is about how much good the core business actually delivers, and to whom.
What a Strong Healthcare BRSR Filing Covers
- Biomedical waste management in India: segregation, digital tracking, and disposal data aligned with CPCB's Bio-Medical Waste Management Rules, not just an annual disposal volume
- Effluent and water discharge data: especially for API and formulation manufacturing units, with third-party verification where possible
- Antimicrobial resistance risk: disclosure of antibiotic residue management in manufacturing effluent, not just workplace infection control
- Workforce wellbeing metrics: burnout indicators, staff turnover, occupational safety incidents across both clinical and plant staff
- Access and affordability data: pricing strategy for essential medicines, reach of services into underserved geographies
- Green hospital infrastructure: energy and water efficiency metrics for hospital buildings, not just manufacturing facilities
- Value chain disclosure: supplier and distributor practices, especially for pharma companies with multi-tier API sourcing
Where This Leaves Healthcare and Pharma Companies
The practical shape of BRSR for healthcare companies comes down to three datasets that too often live in separate departments: biomedical waste tracking data from facilities and hospital operations, effluent and water discharge data from pharmaceutical manufacturing, and workforce wellbeing data covering both clinical staff and plant workers. Each of these feeds a different BRSR principle. Still, investors, sector-specific ESG frameworks, and, for biomedical waste specifically, CPCB's own digital tracking requirements increasingly demand each. Building one system that captures all three, rather than leaving biomedical waste compliance with facilities teams, effluent data with manufacturing quality teams, and staff wellbeing data with HR, is the same efficiency move paying off across every sector in this series.
The credibility test for healthcare and pharma companies is a little different from other industries, too. A thin or vague BRSR for healthcare companies filing is more likely to be read charitably by default, right up until an incident- a pharmaceutical effluent India controversy, a biomedical waste mishandling case, a workforce burnout story- forces a harder look. Getting ahead of that with genuinely detailed, verifiable disclosure isn't just good compliance. In a sector this dependent on public confidence, it's protecting the foundation the business is actually built on.
BRSR Weekly
One practical ESG tip for Indian businesses. No spam.


